GFAP and Alzheimer disease: Moreover, recent literature underlines an incipient role of peripheral biomarkers (in particular blood based biomarkers as plasma P-tau epitopes, P-tau181, P-tau217, P-tau231, NfL and GFAP [30] but also other peripheral noninvasive biomarkers as plasma micro RNAs (miRNAs) profiling also in terms of Extracellular Vesicles’ “cargo” [31] that track different aspects of the disease as synaptic dysfunction, neuro-inflammation, and glial activation, useful for early diagnosis of MCI, AD and differential diagnosis of AD from other neurodegenerative diseases.